Keywords
necrotizing enterocolitis, neonatal enterocolitis, mesenchymal stromal cells, stem cells, preclinical, animal models, systematic review protocol
necrotizing enterocolitis, neonatal enterocolitis, mesenchymal stromal cells, stem cells, preclinical, animal models, systematic review protocol
MSC: mesenchymal stromal cell
NEC: necrotizing enterocolitis
Necrotizing enterocolitis (NEC) is an acute inflammatory disease of the intestine.1,2 It was first described by Mizrahi et al. in 1965.3 This disease is characterized by inflammation and injury to the wall barrier of the intestine that can cause necrosis and that can lead to bowel perforation.2,4,5 It is a major complication of preterm birth.6,7 In Canada, the preterm birth rate is 7.7%8 and, on the basis of large databases, the mean prevalence of NEC in Canada and the United States is about 7% among infants with birth weight between 500 g and 1500 g1,9,10 with a mortality rate as high as 50% in neonates with a birth weight less than 1000 g.11,12 The pathogenesis of NEC is multifactorial.13 The most common known risk factors of NEC include low gestational age, low birth weight, exposure to infant formula-feeding and microbial dysbiosis.2,4,13,14 The classic NEC pathophysiological process of intestinal injury appears to be related to a basic immaturity of host defences, culminating in an excessive inflammatory response, with serum cytokines and chemokines, especially IL-8 significantly elevated15–17 and imbalance of the healthy microbiome.
Survivors of a NEC episode are at increased risk of long-term adverse outcomes including gastrointestinal failure and neurodevelopmental complications.4,12 Because the disease occurs during an important time of brain development, the long-term NEC-associated neurodevelopment outcomes include cerebral palsy and visual, cognitive and psychomotor impairment.4,18–23 NEC also significantly increases hospital length of stay and health care costs. Infants with NEC needing medical treatment are hospitalized on average 22 days longer in the neonatal intensive care unit than neonates without NEC, and those who require surgical treatment are hospitalized 60 days longer than infants without NEC.24 In the USA, the estimated average cost for medical and surgical treatment of NEC is $500 000 per patient.24,25
Current treatment strategies depend on the severity of the disease and remain supportive only. They include bowel rest and decompression, fluid support, vasopressors and systemic broad-spectrum-antibiotics.4,13,26 Surgical treatment of NEC is recommended if bowel perforation occurs or in some cases of bowel necrosis.13 In order to reduce the morbidity and mortality associated with this inflammatory disease, evaluation of new therapies is required. Several treatments have been studied in preclinical trials, including the utilization of mesenchymal stromal cells (MSCs).
MSCs were described in 1976 as fibroblast precursor cells with a role in the regulation of murine hematopoietic stem cells in bone marrow.27 Following this, multiple preclinical studies have shown a repair ability of MSCs in multiple injured organs and tissues of neonatal models such as in the brain,28–32 heart33 lungs34,35 gut36,37 and eyes.38 MSCs are known to have anti-inflammatory properties39 and considering that inflammation plays a key role in the pathogenesis of NEC, they may represent a promising therapeutic option for this disease. In 2020, a systematic review and meta-analysis of preclinical studies using animal models of NEC with stem cells products was published.40 This study suggests a benefit of stem cells in rodent models. However, the research in stem cells is a rapid-growing field in medicine and we believe that an update review with broad inclusion criteria is needed.
We aim to conduct a systematic review of the benefits and harms of MSC therapy in preclinical models of NEC. We seek to look for any clinical effect of this therapy in animal models. We will specifically address the question: In controlled preclinical studies of necrotizing enterocolitis, can MSCs reduce the histological signs of NEC in NEC-induced animal models? Our population of interest is all animal studies of NEC and we are interested in any such studies that use MSCs or any other cell therapy as an intervention. We are interested in all comparisons in the literature. Our primary outcome is histology showing NEC. The following additional outcomes will be measured: survival, bowel perforation, gut permeability, gut motility, levels of inflammatory markers, cytokine levels and adverse events.
This study protocol was developed through discussion between our research team which includes clinical and preclinical research experts (CMB, EH, BT, EF), an information specialist (BS), and research methodologists with expertise in knowledge synthesis (NA, KDC). The protocol was prepared using the PRISMA-P reporting guidelines41 and the protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies published by de Vries et al.42 This protocol was registered using the Open Science Framework (osf.io/5rc6t). A completed PRISMA-P checklist for this protocol is provided. Post-hoc modifications to the current protocol incurred during the review process will be documented in the publication of the final report to ensure transparency.
We will include all study designs of research describing preclinical NEC models that evaluate the efficacy of MSCs or other cell therapy treatments that are published in English. Potentially relevant non-English materials will be provided in the appendix section but will not be included in the analysis. We will not limit our eligibility criteria by year of publication or publication status. Details on the study PICOS are provided below.
Population
The population will include all preclinical in vivo animal models of experimentally induced NEC. To enhance the generalizability of our findings, NEC will be defined as any histological intestinal tissue injury. Various mechanisms of NEC have been reported in animal models in the literature.43,44 These include gavage formula or hyperosmolar formula gavage feeds, exposure to hypoxia and/or hypothermia and administration of bacteria.
Intervention
The intervention of interest is all MSCs cell types, independent of the source, in animal models. MSCs will be defined by using the International Society for Cellular Therapy consensus statement. The minimal criteria to meet to define human MSC are: (1) adhesion to plastic; (2) expression of the cell surface markers CD105, CD73 and CD90 and lack of CD45, CD34, CD14 or CD11b, CD79ɑ or CD19 and HLA-DR surface molecules expression and (3) differentiation to osteoblasts, adipocytes and chondroblasts in vitro.45
All types of MSCs will be considered in the review to enhance the generalizability of our study findings. Any therapeutic MSCs regimen (prophylactic – before or during induction of NEC, or rescue after induction of NEC) will be considered.
Comparison
In our population study of experimental animal models of NEC, we will consider all types of reported comparator. We will also consider groups with no comparator.
Outcome
The primary outcome is histological signs of NEC measured at any time after the administration of MSCs. The secondary outcomes measured are: survival, bowel perforation, gut permeability (e.g. disruption of thigh junction proteins, liver fatty acid-binding protein level and intestinal fatty acid binding protein level), gut motility, levels of inflammatory markers (e.g. white blood cells count, C-reactive protein level and fecal calprotectine) cytokine levels (e.g., interleukine-8 and toll-like receptor 4) and any describe adverse events.
Study design
We will include any study design in the search including both comparative and non-comparative studies as well as empirical research.
We have identified one parent of a preterm infant who suffered from NEC and its complications who engaged in the design of the project and provided feedback after reading the protocol manuscript. The engagement of this parent will be an important addition to our team for subsequent research leading to clinical trial preparation and conduct.
Search strategy
The search strategies will be developed and tested through an iterative process by an experienced medical information specialist in collaboration with the study team members. The MEDLINE strategy will be peer-reviewed by another senior information specialist prior to execution using the Peer Review of Electronic Search Strategies (PRESS) guidelines.46 Proposed databases include MEDLINE, Embase, and Web of Science. Searches will utilize a combination of controlled vocabulary (e.g., “Stem cells”, “Mesenchymal Stem Cells”, “Stromal Cells” and “Enterocolitis, Necrotizing”) and keywords (e.g., “MSCs”, “stromal cell”, “neonatal enterocolitis”). Vocabulary and syntax will be adjusted across the databases. To enhance search efficacy, we will use animal filters validated for Pubmed/MEDLINE and Embase,42,47,48 amended as appropriate to accommodate new developments in vocabulary. There will be no language or date restrictions on any of the searches. We will perform a grey literature search of conference websites and animal research organizations’ websites to identify literature not included in the aforementioned databases, and also perform general searches using Google Scholar.
Data management
DistillerSR (Evidence Partners Inc, Ottawa, Canada) software will be used for records and data management throughout the review. The resulting search citations will be deduplicated and then imported into DistillerSR. Study screening and data extraction forms will be created on the platform to facilitate review of citations obtained from the search.
Selection process
Two reviewers, independently and in duplicate, will carry out citation screening in two stages, reviewing records against the a priori eligibility criteria using an online systematic review software program (Distiller Systematic Review (DSR) Software; Evidence Partners Inc, Ottawa, Canada). At Stage 1, the titles and abstracts of all records obtained from the search will be screened in duplicate independently by CMB and EH while Stage 2 screening will encompass full-text review of the articles deemed potentially relevant at Stage 1. If there are disagreements between the reviewers, it will be resolved by a consensus or by a third member of the study team (EF or BT). Both stages of screening will begin with a calibration exercise to ensure consistent application of eligibility criteria between reviewers. This will include pilot screening of titles and 25 citations at Stage 1 and 25 full-text articles at Stage 2. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,41 the exclusion reasons of potentially eligible studies will be recorded.
Data collection process
The two independent investigators (CMB and EH) conducting screening and extraction will use standardized forms (See drafts, Table 1). These forms will be piloted on a set of 10 documents and then discussed. If necessary, changes to the forms will be made and they will be re-piloted on 10 further documents. This process will be repeated until 80% agreement or higher is reached between the reviewers. We will contact the first author of the included studies once, if necessary, for any missing data.
Data category | Specific items |
---|---|
Study characteristics | Title, name of corresponding author, number of authors, publication date, journal of publication, study design, single vs. multi-centre trial, funding and country of publication of the corresponding author |
Study population | Animal species, sex, age at the time of experimentally induced NEC, age at time of intervention, comorbidity, duration of follow-up, inclusion and exclusion criteria, relevant baseline data. |
Experimental model of necrotizing enterocolitis | Hypercaloric stress, exposure to hypoxia, exposure to hypothermia or other mechanism. |
Intervention | Type of MSCs administered, MSCs’s preparation method before administration (e.g. cells allowed or not to recover for a definite period of time before being administered), time of treatment after the diagnosis of NEC, route given and dosage of MSCs used, unit, duration, frequency, strategy of administration, and co-intervention, etc. |
Comparison | Type and preparation of control suspension, time of treatment after the diagnosis of NEC, unit, duration, frequency, route of administration, strategy of administration, and co-intervention, etc. |
Co-interventions | Fluids, bowel rest, antibiotics, etc. |
Preclinical endpoints | Histological description of intestinal tissue injury, survival, evidence of gut perforation, gut permeability (e.g., disruption of thigh junction proteins, liver fatty acid-binding protein level and intestinal fatty acid binding protein level), gut motility, level of inflammatory markers (e.g., white blood cells count, C-reaction protein and fecal calprotectine), level of cytokines (e.g., interleukine-8 and toll-like receptor 4) and any reported adverse events. |
Risk of bias assessments | In accordance with the elements of the SYRCLE’s risk of bias tool for animal studies50: Random sequence generation, description of baseline animal characteristics, allocation concealment, random animal housing blinding of personnel, blinding of outcome assessment, completeness of outcome data and statement of selective reporting. |
Quality of reporting of individual preclinical studies | In accordance with the elements of the ARRIVE guidelines51 |
Data items
Once all studies are identified, data extraction will be performed using a standardized data extraction form in Microsoft Excel (Microsoft Corporation, Seattle, Washington, USA). We will collect data related to key study items that include but not limited to variables in Table 1 below. If means and measures of dispersion are reported via figures in the primary studies, they will be approximated using online tools such as Webplotdigitizer (A. Rohatgi, 2020, Pacifica, California, USA).
The primary outcome is histological signs of NEC measured at any time after the administration of MSCs. The histological signs can be tissue inflammation, bacterial invasion, tissue necrosis and signs of micro-perforation. If applicable, we will use the standard histologic scoring previously described in the literature to assess the severity of histological changes in NEC.43,49 Histopathology of the lesions will be categorized in four classes: grade 1 focal, mild injury confined to villous types, grade II, partial loss of vili, grade III, necrosis extending to submucosa and grade IV, transmural necrosis.
The secondary outcomes measured will be: survival, bowel perforation, gut permeability, gut motility, levels of inflammatory markers, cytokine levels and any reported adverse events. Survival will be measured in number of days between the diagnosis of NEC and unintentional death. Bowel perforation will be defined as any free air in the abdominal cavity on imaging or visualization of a hole in the wall of the intestinal barrier by direct visualization or by histology. Any possible parameters to assess gut permeability (including but not restricted to disruption of thigh junction proteins, liver fatty acid-binding protein level and intestinal fatty acid binding protein level) and motility will be considered as a valid measure for these outcomes. Any kind of inflammatory markers (including but not restricted to white blood cells count (cells × 109/L), C-reactive protein (mg/L) and fecal calprotectine (mcg/g)) and cytokine levels (including but not restricted to interleukine-8 (pg/mL) and present of toll-like receptor 4) will be recorded. All reported adverse events will be considered.
Two independent investigators (CMB and EH) will evaluate the risk of bias for each study included in the review. We will use the SYRCLE’s risk of bias tool for animal studies.50 This tool was created to establish consistency and avoid discrepancies in the assessment of risk of bias in systematic reviews of animal intervention studies. Each item will be assigned a value of low, high or unclear. Elements of the SYRCLE’s tool include assessment of method used for the sequence generation, description of baseline animal characteristics, allocation concealment, random animal housing, blinding of outcome assessment, random outcome assessment, completeness of outcome data and statement of selective outcome reporting.
Descriptive statistics and tables of evidence summary will be reported. Study characteristics will be summarized using frequencies and percentages. As a rule, heterogeneity that may be explained by clinical or methodological differences between studies will preclude any planned meta-analyses. If so, study results will be synthesized narratively. Outcomes with dichotomous endpoints (e.g., survival and presence of intestinal perforation) from each included study will be pooled and described using risk ratio and/or odds ratios and 95% confidence intervals that incorporate a random effect modelling approach. We will use forest plots to visualize the data. Statistical heterogeneity between studies will be quantified with I-squared statistics. Sparse data will not be meta-analyzed but described narratively. Outcomes with continuous endpoints (e.g., gut permeability, gut motility, levels of inflammatory markers and cytokine levels) will be pooled using mean difference or standardized mean difference. Meta-regression with multiple study level covariates will be attempted when there are at least 10 studies in the body of evidence. Otherwise, clinical and methodological diversity in studies will be explored in pre-specified subgroup and sensitivity analyses. We will analyze subgroups for the following: animal models, sex, experimental model of NEC (e.g., hypercaloric stress, exposure to hypoxia or exposure to hypothermia), administration route of MSC (e.g., intravenous or intraperitoneal), dose of MSC, timing of MSC administration after induction of NEC (less or equal to one hour, greater than one hour to less or equal to four hours, more than four hours or multiple doses), other treatment used and control group. To assess the potential meta-bias and publication bias, we will use the funnel plot as a graphical tool. The quality of reporting of individual preclinical studies will be assessed in accordance with the elements of the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines.51
This study is a systematic review of animal models and there will be no direct interaction with animals or patients. The systematic review is planned to be conducted between March and September 2021. The results of this study will be presented to the scientific community at pertinent national and international meetings. We will also publish the results of the systematic review in peer-reviewed scientific journals. The general public will be informed through various local and national associations and media.
NEC is an important inflammatory disease that affects infants and the current treatment is supportive. In order to reduce the mortality and the morbidity associated with this disease, there is a need for new treatment targeting the inflammation process and MSCs may be beneficial. To our knowledge, no systematic review of the use of MSCs in preclinical models for NEC has been reported. The data from this review will provide information on whether there is sufficient rigorous evidence to support a clinical trial testing the feasibility and safety of MSC therapy in neonates with NEC. If not, this study will illustrate any gaps in the field which can guide the design of future research studies to address those issues.
Open Science Framework: PRISMA-P checklist for ‘Efficacy of mesenchymal stromal cells in preclinical models of necrotizing enterocolitis: a systematic review protocol’, https://doi.org/10.17605/OSF.IO/YJNXP.
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
An earlier version of this article can be found on Research Square (doi: 10.21203/rs.3.rs-239448/v1).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
References
1. Villamor-Martinez E, Hundscheid T, Kramer BW, Hooijmans CR, et al.: Stem Cells as Therapy for Necrotizing Enterocolitis: A Systematic Review and Meta-Analysis of Preclinical Studies.Front Pediatr. 2020; 8: 578984 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: intestinal inflammation, ER stress, microbiome
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Neonatal nutrition and metabolism
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 05 Oct 21 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)